Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Biomarin Pharmaceutical stock price, quote, forecast and news

BMRN
US09061G1013
924801

Price

70.55
Today +/-
+0.62
Today %
+0.98 %
P

Biomarin Pharmaceutical stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Biomarin Pharmaceutical stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Biomarin Pharmaceutical stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Biomarin Pharmaceutical stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Biomarin Pharmaceutical's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Biomarin Pharmaceutical Stock Price History

DateBiomarin Pharmaceutical Price
9/17/202470.55 undefined
9/16/202469.86 undefined
9/13/202484.90 undefined
9/12/202484.38 undefined
9/11/202484.78 undefined
9/10/202484.85 undefined
9/9/202484.33 undefined
9/6/202484.08 undefined
9/5/202485.12 undefined
9/4/202489.86 undefined
9/3/202491.60 undefined
8/30/202491.21 undefined
8/29/202491.37 undefined
8/28/202490.32 undefined
8/27/202490.46 undefined
8/26/202489.98 undefined
8/23/202490.02 undefined
8/22/202490.02 undefined
8/21/202492.57 undefined
8/20/202493.84 undefined

Biomarin Pharmaceutical Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Biomarin Pharmaceutical, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Biomarin Pharmaceutical from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Biomarin Pharmaceutical’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Biomarin Pharmaceutical. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Biomarin Pharmaceutical’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Biomarin Pharmaceutical’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Biomarin Pharmaceutical’s growth potential.

Biomarin Pharmaceutical Revenue, EBIT and net profit per share

DateBiomarin Pharmaceutical RevenueBiomarin Pharmaceutical EBITBiomarin Pharmaceutical Net Income
2029e4.59 B undefined0 undefined1.49 B undefined
2028e4.3 B undefined1.29 B undefined1.33 B undefined
2027e3.9 B undefined1.11 B undefined1.14 B undefined
2026e3.54 B undefined947.91 M undefined824.59 M undefined
2025e3.18 B undefined682.58 M undefined615.32 M undefined
2024e2.86 B undefined410.91 M undefined396.1 M undefined
20232.42 B undefined158.1 M undefined167.65 M undefined
20222.1 B undefined64.6 M undefined141.6 M undefined
20211.85 B undefined-83.8 M undefined-64.1 M undefined
20201.86 B undefined-96.4 M undefined859.1 M undefined
20191.7 B undefined-120.2 M undefined-23.8 M undefined
20181.49 B undefined-179.2 M undefined-77.2 M undefined
20171.31 B undefined-150.5 M undefined-117 M undefined
20161.12 B undefined-200.7 M undefined-630.2 M undefined
2015889.9 M undefined-285.3 M undefined-171.8 M undefined
2014749.3 M undefined-168.1 M undefined-134 M undefined
2013548.5 M undefined-151.1 M undefined-176.4 M undefined
2012500.7 M undefined-111.8 M undefined-114.3 M undefined
2011441.4 M undefined-33.1 M undefined-53.8 M undefined
2010376.3 M undefined-1.3 M undefined205.8 M undefined
2009324.7 M undefined16.4 M undefined-500,000 undefined
2008296.5 M undefined39.8 M undefined30.8 M undefined
2007121.6 M undefined-57.3 M undefined-15.8 M undefined
200684.2 M undefined-43.4 M undefined-28.5 M undefined
200525.7 M undefined-76 M undefined-74.3 M undefined
200418.6 M undefined-76.7 M undefined-187.4 M undefined

Biomarin Pharmaceutical Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000.010.01000.010.020.030.080.120.30.320.380.440.50.550.750.891.121.311.491.71.861.852.12.422.863.183.543.94.34.59
---80.00---50.0038.89236.0044.05144.639.4616.0517.2913.389.6036.6818.6925.5317.6513.5614.299.15-0.7513.5415.4118.1111.1711.3410.3810.276.62
------100.0077.7892.0089.2985.1282.4379.6381.3880.9581.6082.4883.7182.9081.2781.5778.8178.8771.8374.4976.9178.71------
0000000.010.010.020.080.10.240.260.310.360.410.450.630.740.911.071.181.341.341.381.611.9000000
-0-0.01-0.03-0.04-0.03-0.04-0.06-0.08-0.08-0.04-0.060.040.02-0-0.03-0.11-0.15-0.17-0.29-0.2-0.15-0.18-0.12-0.1-0.080.060.160.410.680.951.111.290
---500.00-388.89---475.00-422.22-304.00-51.19-47.1113.184.94-0.27-7.48-22.20-27.55-22.43-32.06-17.92-11.42-12.01-7.04-5.16-4.503.056.5314.3521.4726.7828.4430.04-
-0-0.01-0.03-0.04-0.07-0.08-0.08-0.19-0.07-0.03-0.020.0300.21-0.05-0.11-0.18-0.13-0.17-0.63-0.12-0.08-0.020.86-0.060.140.170.40.620.821.141.331.49
-500.00133.3332.1481.0814.93-2.60149.33-60.43-62.16-46.43-300.00---125.85115.0954.39-23.8627.61268.42-81.43-34.19-70.13-3,834.78-107.45-320.3118.44137.1355.3033.9837.7417.2711.87
8.122.529.935.941.153.362.164.468.884.695.9103.6100.3125.7112.1120.3137.8146.3160166174.4177.1179191.7182.9189191.6000000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Biomarin Pharmaceutical Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Biomarin Pharmaceutical is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                     
0.010.010.060.040.140.080.210.050.050.290.590.560.30.270.20.450.780.950.590.791.41.080.751.071.011.291.07
0.10.72.51.800045.914.71784.373.586.6104.8109.1117.8144.5165215.3261.4342.6377.4448.4373.4461.3633.7
00000000004.54.87.17.30009.714.100000000
000000000.010.030.030.070.080.110.130.130.160.20.270.360.480.530.680.70.780.891.11
0.50.70.32.52.62.12.927.83.342.815.47.826.639.857.972.398.846.361.77498.4130.7129.9110.4104.5141.39
0.010.010.070.040.140.080.210.090.070.330.640.740.470.50.470.741.141.41.091.422.212.061.942.342.272.752.96
00.010.030.020.030.030.030.040.040.060.080.130.20.220.270.280.320.520.70.80.90.951.071.091.081.111.11
00.70.41.5001223.13231.544.92.5170.3129.394.9117.1268.597.9425.7572.7385.8235.9412285.5507.8333.8622.44
000000000000000000000000000
011.711.5000016.515.311.79.67.641103.6180.3163163.1156.6684553.8517.5491.8456.6417.3388.7338.6294.7
000000045.121.321.321.321.323.753.451.551.554.354.3197197197197197196.2196.2196.2196.2
0000.01000.010.020.020.010.020.010.020.250.240.210.30.250.630.480.430.50.611.521.551.641.66
00.020.040.030.030.030.040.150.130.130.170.170.450.760.840.821.111.082.642.62.432.372.753.513.733.623.89
0.010.030.10.080.170.110.260.230.20.460.820.910.921.261.311.572.242.483.734.024.634.434.695.8566.386.84
                                                     
0000100100100100100100100100100100100100100100200200200200200200200200189
0.010.050.140.150.310.320.420.420.490.710.790.850.91.091.21.562.062.363.414.294.484.674.834.995.195.45.61
-2.8-15.1-43.1-80.5-148.1-225.6-301.4-488.8-563.1-591.6-607.4-576.6-577.1-371.3-425.1-539.4-715.8-849.8-1,021.6-1,520.5-1,637.5-1,694.1-1,720.7-861.6-925.7-789.2-621.55
-0.2-3.3-2.6-1.5-0.70.3-0.2-0.4000.10.2-0.8-1.81-6.8-2.417.87.4-1.5-34.5-6.16.6-29.96.1-0.6-39.52
00000000000000000000-2.7-1.93.63.9-1.4-12.10.87
0.010.030.10.070.160.10.12-0.07-0.080.120.190.280.320.720.771.021.341.532.42.772.812.973.124.114.274.64.95
0.31.33.14.64.30.10.40.90.52.31.20.97.6502436.9144.4186.2198.5161.7208.1241191.4193231.2315.51
00.6222.23.89.724.418.326.347.157.361.567.975.6117.1136.881.9197.9158.9201.6213287.9266.3277.1317.8322.84
0000.30.2001.910.310.76.91.19.11118.569.69.461.359.492.3102.138.53267.537.544.66
00000000000000023.400000000000
00001.62.92.742.811.36.86.370.7000000022.5360.90365.12.92.32.3494.02
000.010.010.010.010.010.070.040.050.060.130.080.080.090.170.180.240.450.440.820.520.930.490.540.591.18
000000.010.130.230.210.290.560.50.50.380.350.320.660.640.660.660.810.830.491.081.081.080.59
0000000000002.536.537.2000143.500000000
00000002.919.57.12.12.617.247.553.157.364.268.877.3157.3194.4105.5142.2170.3111.799.8119.86
000000.010.130.230.230.30.570.50.520.460.440.380.720.710.880.821.010.940.641.251.191.180.71
000.010.010.010.010.140.30.270.350.630.630.60.550.530.550.90.951.331.261.821.461.571.741.731.771.89
0.010.030.10.080.170.110.260.230.20.460.820.910.921.261.311.572.242.483.734.024.634.434.695.8566.376.84
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Biomarin Pharmaceutical provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Biomarin Pharmaceutical's financial health and stability.

Assets

Biomarin Pharmaceutical's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Biomarin Pharmaceutical must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Biomarin Pharmaceutical after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Biomarin Pharmaceutical's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (k)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-2-12-26-35-57-77-76-187-74-28-15300205-53-114-176-134-171-630-117-77-23859-64141167
004578913911131721273644364547968795105105108102104
0000000000000-2304-9-8-25-76-22844-68-82-888-15-52-44
0020-2-261211-29-14-8919-42-2533-8-1546-160-94-49-101-22466-96-336
0264111716107-5-6-1859839610111116414547828210268310424407277475
00071602552710910762998811812101010
000000000001234614351695231699185473
-3-8-12-26-40-53-43-54-59-52-35-987181817-57-70-219-227-8204885304175159
0-6-22-3-17-4-6-20-6-24-22-56-89-49-154-44-65-117-227-148-199-144-163-137-119-131-107
-1-8-6812-11670-82-2654-192-150-19-79-101-89-195-298196-1,179-484-305264-31-53-366-20-111
0-1-4515-9875-76-560-168-1283710-5164-151-233313-951-335-10640913283-247111-3
000000000000000000000000000
0025050118-29-34155309-6-73-14-30713000481-375-5203-3-2-2
91970614719416414015291133343197319795178760673121496969
10199571533213-273029532422-63329312746184925727507-388-741810-18-18
000001,000000000-1,000-15,000-1,000-6,000-39,000-13,000-25,000-60,000-35,000-80,000-101,000-44,000-46,000-85,000-85,000
000000000000000000000000000
5314-6-42187-1082551139-5-55-79-41134388306-47811189-104-56211-6113730
-3.3-14.5-35.8-30.2-58.7-58.5-49.1-75.1-65.7-76.9-57.4-65.6-2.1-30.8-135.4-27-122.5-187.5-447.2-376.2-208-124.4-115.1-52.1185.344.451.65
000000000000000000000000000

Biomarin Pharmaceutical stock margins

The Biomarin Pharmaceutical margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biomarin Pharmaceutical. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biomarin Pharmaceutical.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Biomarin Pharmaceutical's sales revenue. A higher gross margin percentage indicates that the Biomarin Pharmaceutical retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Biomarin Pharmaceutical's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Biomarin Pharmaceutical's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Biomarin Pharmaceutical's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Biomarin Pharmaceutical. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Biomarin Pharmaceutical's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Biomarin Pharmaceutical Margin History

Biomarin Pharmaceutical Gross marginBiomarin Pharmaceutical Profit marginBiomarin Pharmaceutical EBIT marginBiomarin Pharmaceutical Profit margin
2029e78.72 %0 %32.45 %
2028e78.72 %30.04 %30.95 %
2027e78.72 %28.44 %29.09 %
2026e78.72 %26.81 %23.32 %
2025e78.72 %21.49 %19.37 %
2024e78.72 %14.38 %13.86 %
202378.72 %6.54 %6.93 %
202276.93 %3.08 %6.76 %
202174.52 %-4.54 %-3.47 %
202071.82 %-5.18 %46.18 %
201978.91 %-7.05 %-1.4 %
201878.86 %-12.02 %-5.18 %
201781.6 %-11.46 %-8.91 %
201681.22 %-17.97 %-56.42 %
201582.92 %-32.06 %-19.31 %
201483.68 %-22.43 %-17.88 %
201382.53 %-27.55 %-32.16 %
201281.67 %-22.33 %-22.83 %
201180.95 %-7.5 %-12.19 %
201081.32 %-0.35 %54.69 %
200979.67 %5.05 %-0.15 %
200882.29 %13.42 %10.39 %
200784.87 %-47.12 %-12.99 %
200689.67 %-51.54 %-33.85 %
200589.49 %-295.72 %-289.11 %
200479.03 %-412.37 %-1,007.53 %

Biomarin Pharmaceutical Stock Sales Revenue, EBIT, Earnings per Share

The Biomarin Pharmaceutical earnings per share therefore indicates how much revenue Biomarin Pharmaceutical has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biomarin Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biomarin Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biomarin Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biomarin Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biomarin Pharmaceutical Revenue, EBIT and net profit per share

DateBiomarin Pharmaceutical Sales per ShareBiomarin Pharmaceutical EBIT per shareBiomarin Pharmaceutical Earnings per Share
2029e24.1 undefined0 undefined7.82 undefined
2028e22.61 undefined0 undefined7 undefined
2027e20.5 undefined0 undefined5.96 undefined
2026e18.57 undefined0 undefined4.33 undefined
2025e16.68 undefined0 undefined3.23 undefined
2024e15.01 undefined0 undefined2.08 undefined
202312.63 undefined0.83 undefined0.87 undefined
202211.09 undefined0.34 undefined0.75 undefined
202110.09 undefined-0.46 undefined-0.35 undefined
20209.71 undefined-0.5 undefined4.48 undefined
20199.52 undefined-0.67 undefined-0.13 undefined
20188.42 undefined-1.01 undefined-0.44 undefined
20177.53 undefined-0.86 undefined-0.67 undefined
20166.73 undefined-1.21 undefined-3.8 undefined
20155.56 undefined-1.78 undefined-1.07 undefined
20145.12 undefined-1.15 undefined-0.92 undefined
20133.98 undefined-1.1 undefined-1.28 undefined
20124.16 undefined-0.93 undefined-0.95 undefined
20113.94 undefined-0.3 undefined-0.48 undefined
20102.99 undefined-0.01 undefined1.64 undefined
20093.24 undefined0.16 undefined-0 undefined
20082.86 undefined0.38 undefined0.3 undefined
20071.27 undefined-0.6 undefined-0.16 undefined
20061 undefined-0.51 undefined-0.34 undefined
20050.37 undefined-1.1 undefined-1.08 undefined
20040.29 undefined-1.19 undefined-2.91 undefined

Biomarin Pharmaceutical business model

Biomarin Pharmaceutical Inc is a biopharmaceutical company that focuses on the development and commercialization of therapies for rare genetic diseases. The company was founded in 1997 and is headquartered in San Rafael, California. Biomarin Pharmaceutical is one of the most popular companies on Eulerpool.com.

Biomarin Pharmaceutical revenue by segment

In the annual report of the Biomarin Pharmaceutical share (US09061G1013, 924801, BMRN), it breaks down its revenues into 1 segments: 1. Development & Commercialization of Innovative Therapies. The Biomarin Pharmaceutical stock (WKN: 924801, ISIN: US09061G1013, Ticker Symbol: BMRN) is a leading investment for investors interested in participating in the Health Care sector.

  • 100 % Development & Commercialization of Innovative Therapies

Biomarin Pharmaceutical Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Biomarin Pharmaceutical Revenue by Segment

Segmente202320222021202020192018
Product--1.78 B USD1.81 B USD1.66 B USD-
Net product revenues2.37 B USD2.04 B USD----
Net Product Revenues-----1.47 B USD
Royalty and Other Revenues--62.78 M USD54.59 M USD43.01 M USD-
Royalty and other revenues46.69 M USD54.01 M USD----
Royalty and other-----20.86 M USD
Aldurazyme--122.77 M USD130.11 M USD97.81 M USD-
Product 1-----135.1 M USD
ALDURAZYME131.25 M USD-----
ALDURAZYME net product revenues marketed by Sanofi-128.42 M USD----
Products excluding ALDURAZYME2.24 B USD-----
Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse---1.68 B USD--
Vimizim---544.26 M USD--
Product 4-----481.98 M USD
Kuvan---457.74 M USD--
Product 3-----433.58 M USD
Naglazyme---391.3 M USD--
Product 2-----345.85 M USD
Palynziq---170.98 M USD--
Brineura---110.19 M USD--
Product six-----39.89 M USD
Product 5-----21.79 M USD
Product 7-----12.17 M USD
Firdapse---1.29 M USD--
Vimizim, Kuvan, Naglazyme, Palynziq, Brineura, and Firdapse--1.66 B USD---
Vimizim----544.35 M USD-
Kuvan----463.35 M USD-
Naglazyme----374.33 M USD-
Palynziq----86.86 M USD-
Brineura----72 M USD-
Firdapse----22.35 M USD-
Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim----1.56 B USD-

Biomarin Pharmaceutical Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Biomarin Pharmaceutical Revenue by Segment

DateEuropeLatin AmericaRest of worldUnited States
2020518.47 M USD205.86 M USD223.75 M USD912.38 M USD
2019509.19 M USD218.79 M USD197.63 M USD778.44 M USD
2018424.36 M USD184.98 M USD165.89 M USD560.03 M USD
2017301.49 M USD182.44 M USD241.48 M USD588.24 M USD
2016252.63 M USD147.47 M USD209.21 M USD507.54 M USD

Biomarin Pharmaceutical Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Biomarin Pharmaceutical historical P/E ratio, EBIT, and P/S ratio.

Biomarin Pharmaceutical shares outstanding

The number of shares was Biomarin Pharmaceutical in 2023 — This indicates how many shares 191.595 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biomarin Pharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biomarin Pharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biomarin Pharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biomarin Pharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Biomarin Pharmaceutical.

Biomarin Pharmaceutical latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.36 0.56  (57.22 %)2024 Q2
3/31/20240.35 0.46  (30.72 %)2024 Q1
12/31/20230.24 0.18  (-24.47 %)2023 Q4
9/30/20230.24 0.21  (-12.06 %)2023 Q3
6/30/20230.24 0.29  (22.11 %)2023 Q2
3/31/20230.18 0.27  (47.54 %)2023 Q1
12/31/2022-0.07 0  (100 %)2022 Q4
9/30/2022-0.01 -0.04  (-359.77 %)2022 Q3
6/30/20220.12 0.15  (29.98 %)2022 Q2
3/31/20220.18 0.18  (2.51 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Biomarin Pharmaceutical stock

Eulerpool World ESG Rating (EESG©)

60/ 100

🌱 Environment

41

👫 Social

99

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
14,000
Scope 2 - Indirect emissions from purchased energy
5,000
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
19,000
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees50
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Biomarin Pharmaceutical list of shareholders

%
Name
Stocks
Change
Date
9.67243 % PRIMECAP Management Company18,414,3747,83512/31/2023
9.43844 % The Vanguard Group, Inc.17,968,901348,31112/31/2023
7.35060 % Dodge & Cox13,994,063-159,44012/31/2023
5.65954 % Capital Research Global Investors10,774,6414,756,67112/31/2023
5.29502 % BlackRock Institutional Trust Company, N.A.10,080,662109,65012/31/2023
3.53531 % State Street Global Advisors (US)6,730,515271,78612/31/2023
2.71007 % Barclays Bank PLC5,159,429259,63412/31/2023
2.56826 % Viking Global Investors LP4,889,454673,99812/31/2023
2.44908 % Columbia Threadneedle Investments (US)4,662,557276,45012/31/2023
2.25864 % Avoro Capital Advisors LLC4,300,000450,00012/31/2023
1
2
3
4
5
...
10

Biomarin Pharmaceutical Executives and Management Board

Mr. Jean-Jacques Bienaime69
Biomarin Pharmaceutical Director (since 2005)
Compensation 18.35 M
Dr. Henry Fuchs65
Biomarin Pharmaceutical President - Worldwide Research and Development
Compensation 8.7 M
Mr. Jeffrey Ajer60
Biomarin Pharmaceutical Executive Vice President, Chief Commercial Officer
Compensation 5.46 M
Dr. C. Greg Guyer61
Biomarin Pharmaceutical Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
Compensation 5.43 M
Mr. G. Eric Davis52
Biomarin Pharmaceutical Executive Vice President, Secretary, Chief Legal Officer
Compensation 5.19 M
1
2
3
4
...
5

Most common questions regarding Biomarin Pharmaceutical

What values and corporate philosophy does Biomarin Pharmaceutical represent?

Biomarin Pharmaceutical Inc is dedicated to improving the lives of patients with rare genetic diseases. The company's corporate philosophy revolves around innovation, collaboration, and integrity. Biomarin strives to develop transformative therapies that address unmet medical needs and provide hope for patients and their families. With a strong commitment to research and development, Biomarin focuses on advancing cutting-edge technologies and delivering life-changing treatments. By partnering with healthcare professionals, patient advocacy groups, and regulatory agencies, Biomarin aims to make a meaningful impact in the field of rare diseases. With its tireless pursuit of excellence, Biomarin Pharmaceutical Inc sets itself apart as a leader in the biopharmaceutical industry.

In which countries and regions is Biomarin Pharmaceutical primarily present?

Biomarin Pharmaceutical Inc is primarily present in various countries and regions worldwide. The company has a global presence and operates in key pharmaceutical markets. Biomarin's significant presence can be observed in the United States, where its headquarters are located. Additionally, Biomarin Pharmaceutical Inc also maintains a strong presence in Europe, including countries like the United Kingdom, Germany, France, and Italy. Furthermore, the company has established a foothold in Asia, with operations in Japan and China. With its extensive international reach, Biomarin Pharmaceutical Inc continues to expand its market presence and deliver innovative therapies to patients globally.

What significant milestones has the company Biomarin Pharmaceutical achieved?

Some significant milestones achieved by Biomarin Pharmaceutical Inc include obtaining FDA approval for several of its innovative therapies, such as Kuvan for Phenylketonuria (PKU) and Vimizim for Morquio A syndrome. The company also successfully launched Naglazyme for Maroteaux-Lamy syndrome and Palynziq for phenylketonuria patients. Biomarin Pharmaceutical Inc has consistently demonstrated its commitment to research and development, focusing on rare genetic diseases. With its dedication to advancing medical treatments, the company continues to make groundbreaking discoveries, improving the lives of patients worldwide.

What is the history and background of the company Biomarin Pharmaceutical?

Biomarin Pharmaceutical Inc, founded in 1997, is a globally recognized biotechnology company headquartered in California. Specializing in developing innovative therapies for rare genetic diseases, Biomarin has established itself as a leader in the field. With a commitment to scientific excellence, the company has gained significant expertise and has successfully brought numerous groundbreaking treatments to market. Biomarin's dedication to improving the lives of patients with rare disorders has made it a trusted name in the pharmaceutical industry. With its strong track record of developing transformative therapies, Biomarin continues to make valuable contributions towards addressing unmet medical needs.

Who are the main competitors of Biomarin Pharmaceutical in the market?

The main competitors of Biomarin Pharmaceutical Inc in the market are competitive biotechnology and pharmaceutical companies such as Alexion Pharmaceuticals, Inc., Sarepta Therapeutics, Inc., and Ultragenyx Pharmaceutical Inc. These companies operate in the same industry and focus on developing innovative therapies for rare genetic diseases and conditions, just like Biomarin Pharmaceutical Inc. These competitors pose challenges to Biomarin Pharmaceutical Inc's market share, as they constantly strive to advance their own treatments and attract patients and healthcare professionals. However, Biomarin Pharmaceutical Inc maintains a strong position in the market with its portfolio of cutting-edge therapies and ongoing research and development efforts.

In which industries is Biomarin Pharmaceutical primarily active?

Biomarin Pharmaceutical Inc primarily operates in the biopharmaceutical industry.

What is the business model of Biomarin Pharmaceutical?

The business model of Biomarin Pharmaceutical Inc is focused on developing and commercializing innovative therapies for rare genetic diseases. The company specializes in developing enzyme replacement therapies and gene therapies to treat a range of genetic disorders. Biomarin Pharmaceutical Inc aims to create life-saving treatments for patients with unmet medical needs, particularly those with rare diseases that have limited treatment options. They collaborate with researchers, clinicians, and patient advocacy groups to bring these therapies to the market. Biomarin Pharmaceutical Inc is committed to providing transformative solutions and improving the lives of patients affected by rare genetic diseases.

What is the P/E ratio of Biomarin Pharmaceutical 2024?

The Biomarin Pharmaceutical P/E ratio is 34.13.

What is the P/S ratio of Biomarin Pharmaceutical 2024?

The Biomarin Pharmaceutical P/S ratio is 4.73.

What is the AlleAktien quality score of Biomarin Pharmaceutical?

The AlleAktien quality score for Biomarin Pharmaceutical is 4/10.

What is the revenue of Biomarin Pharmaceutical 2024?

The expected Biomarin Pharmaceutical revenue is 2.86 B USD.

How high is the profit of Biomarin Pharmaceutical 2024?

The expected Biomarin Pharmaceutical profit is 396.1 M USD.

What is the business model of Biomarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company that develops and markets medications for the treatment of rare genetic diseases. The company focuses on genetics, enzymology, and biology and is dedicated to discovering and developing novel therapies for rare diseases that are often untreated or poorly treated. The company was founded in 1997 and is headquartered in San Rafael, California. BioMarin Pharmaceutical Inc currently operates in over 40 countries and employs over 3,000 people worldwide. BioMarin Pharmaceutical Inc's business model is based on research, development, and marketing of therapeutics for rare diseases. The company is divided into four business segments: therapeutic enzymes, protein and peptide therapies, gene therapies, and neuromuscular diseases. Each of these segments aims to treat specific diseases that have either no or very limited treatment options. The first business segment, therapeutic enzymes, focuses on the development of novel therapeutic options for rare genetic diseases caused by enzyme deficiencies. The main products in this segment are Kuvan and Naglazyme. Kuvan is a medication used to treat phenylketonuria (PKU), a rare disorder that affects the metabolism of phenylalanine. Naglazyme is an enzyme used to treat mucopolysaccharidosis VI (MPS VI), which affects bone growth, metabolism, and the central nervous system. The second business segment, protein and peptide therapies, develops treatments based on proteins and peptides to treat rare diseases. The products produced in this segment include Vimizim, Brineura, and Palynziq. Vimizim is a therapy for the treatment of Morquio A syndrome, a rare disorder that affects bone growth. Brineura is an enzyme replacement therapy for the treatment of a form of neuronal ceroid lipofuscinosis. Palynziq is an injectable enzyme replacement therapy for the treatment of acute enzyme deficiencies in adults with phenylketonuria (PKU). The third business segment, gene therapies, specializes in developing treatment options for genetic changes related to diseases. The company is currently developing a gene therapy for hemophilia A, a chronic genetic disorder caused by a missing clotting factor protein. The fourth business segment, neuromuscular diseases, develops therapies for the treatment of rare muscular diseases. The company is currently working on developing therapies for infantile and childhood diseases such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). An example product in this segment is BMN 250, a gene therapy for DMD. Overall, BioMarin Pharmaceutical Inc provides therapeutic treatment options for patients suffering from rare and severe diseases. By consistently advancing in research and development, the company has been able to expand its market position in this niche. The company is particularly focused on achieving a long-term goal: improving the quality of life for patients by developing treatment options for diseases that currently have insufficient treatment options.

What is the Biomarin Pharmaceutical dividend?

Biomarin Pharmaceutical pays a dividend of 0 USD distributed over payouts per year.

How often does Biomarin Pharmaceutical pay dividends?

The dividend cannot currently be calculated for Biomarin Pharmaceutical or the company does not pay out a dividend.

What is the Biomarin Pharmaceutical ISIN?

The ISIN of Biomarin Pharmaceutical is US09061G1013.

What is the Biomarin Pharmaceutical WKN?

The WKN of Biomarin Pharmaceutical is 924801.

What is the Biomarin Pharmaceutical ticker?

The ticker of Biomarin Pharmaceutical is BMRN.

How much dividend does Biomarin Pharmaceutical pay?

Over the past 12 months, Biomarin Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biomarin Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Biomarin Pharmaceutical?

The current dividend yield of Biomarin Pharmaceutical is .

When does Biomarin Pharmaceutical pay dividends?

Biomarin Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biomarin Pharmaceutical?

Biomarin Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Biomarin Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biomarin Pharmaceutical located?

Biomarin Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biomarin Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biomarin Pharmaceutical from 9/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/19/2024.

When did Biomarin Pharmaceutical pay the last dividend?

The last dividend was paid out on 9/19/2024.

What was the dividend of Biomarin Pharmaceutical in the year 2023?

In the year 2023, Biomarin Pharmaceutical distributed 0 USD as dividends.

In which currency does Biomarin Pharmaceutical pay out the dividend?

The dividends of Biomarin Pharmaceutical are distributed in USD.

All fundamentals about Biomarin Pharmaceutical

Our stock analysis for Biomarin Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomarin Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.